Plasmid IL-12 Added to Pembrolizumab Elicits Deep and Durable Responses in Advanced Melanoma

Source: Targeted Oncology, November 2020

The strategy of adding the plasmid IL-12 (pIL-12-EP) agent tavokinogene telseplasmid to pembrolizumab (Keytruda) led to deep systemic responses in patients with actively progressing anti–PD-1–refractory advanced melanoma, according to interim results from the KEYNOTE-695 clinical trial (NCT03132675).

Interim data presented during the Society for Immunotherapy of Cancer (SITC) Virtual Annual Meeting 2020 by Adil Daud, MD, was from 56 out of 100 patients with unresectable or metastatic melanoma who received anti–PD-1 therapy alone or in combination with another agent for 12 weeks prior to study entry.